Thomas Lahiri

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1

Changing Epidemiology of Life-Threatening Upper Airway Infections: The Reemergence of Bacterial Tracheitis

Amelia Hopkins, Thomas Lahiri, Richard Salerno et al. · PEDIATRICS · 2006 · 89 citations

Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery?

Kristina W. Rosbe, Dwight T. Jones, Reza Rahbar et al. · International Journal of Pediatric Otorhinolaryngology · 2001 · 73 citations

Endoscopic Surgery, Endoscopic Sinus Surgery, Surgery +4

Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort

Margaret Rosenfeld, Julia Emerson, Sharon McNamara et al. · Pediatric Pulmonology · 2010 · 60 citations